BioSpace News Archive

AstraZeneca and Daiichi Sankyo’s ENHERTU® (fam-trastuzumab deruxtecan-nxki) met the prespecified target for objective response rate (ORR) and demonstrated durable response across multiple HER2-expressing advanced solid tumors in heavily pretreated patients.

Zevra Therapeutics, Inc. today announced that Richard W. Pascoe, the Company’s Chief Executive Officer, will participate in a fireside chat at the 35th Annual Roth Conference on Monday, March 13, 2023, at 2:00 p.m. PT.

Relay Therapeutics, Inc. today announced that initial clinical data from the ReDiscover trial for RLY-2608 have been selected for presentation at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2023, being held April 14-19, 2023.

Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced financial results for the fourth quarter and year ended December 31, 2022.

Windtree Therapeutics, Inc., a biotechnology company focused on advancing late-stage interventions for cardiovascular disorders, is targeting cardiogenic shock as a potential indication for its drug candidate, istaroxime and announces results of a recently completed market study.

Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for IK-175, the Company’s novel aryl hydrocarbon receptor (AHR) antagonist, in combination with immune checkpoint inhibitors in patients with advanced urothelial carcinoma who have progressed on or within three months of receiving the last dose of checkpoint inhibitors.

Harbour BioMed announces the positive topline results of its phase III clinical trial of batoclimab for the treatment of generalized myasthenia gravis, which is also the first positive pivotal trial outcome for batoclimab worldwide.

NeoDynamics AB, a medical device company dedicated to advancing the diagnosis and care of cancer, announced that the Company has been granted a Chinese patent for the needle design employed in the NeoNavia® FlexiPulse™ probe.

Armata Pharmaceuticals, Inc. today announced positive topline results from the completed Phase 1b/2a SWARM-P.a. trial evaluating AP-PA02, a novel, inhaled multi-phage therapeutic for the treatment of chronic pulmonary Pseudomonas aeruginosa infections in cystic fibrosis patients.

Kineta, Inc. announced today it will host a virtual Key Opinion Leader (KOL) event on VISTA as an immuno-oncology target on Monday, March 20, 2023 at 10:00 AM ET.